INTRODUCTION Atazanavir Sulphate Methyl is a Antiretroviral drug N-[(1S)-1-{ [(2S,3S) -3 -hydroxy-4-[(2S)-2-[(methoxycarbonyl) amino] -3, 3 -dimethyl -N' -{[4-(pyridin-
2
EXPERIMENTAL Reagents and Chemicals
Ritonavir API and atanavir API were obtained as gift sample from sura labs. Acetonitrile,Water, methanol is used of HPLC grade and purchased
Instrumentation
Chromatographic separation was performed on a Waters HPLC with auto sampler and PDA Detector 996.variablewavelength programmable UV/VIS detector, Phenomenex Gemini C18 (4.6×150mm, 5µ) with10μl fixed loop.
Chromatographic conditions
Phenomenex Gemini C18 (4.6×150mm, 5µ) were the column used for separation. Mobile phase Containing a mixture of Methanol: Water (90:10% v/v) in 1000 ml of water and pH was adjusted to 4.2 in the ratio 50:50 v/v was delivered at a flow rate of 1.0 ml/min with detection at 249nm. The mobile phase is filtered through a 0.45 nylon filter and sonicated for 20 min.
Method development
Acetonitrile, methanol and water in different proportions were tried and finally Methanol: Water = 90:10v/v was selected appropriate mobile phase which gave good resolution, retention time and acceptable system suitability parameters.
Procedure Preparation of standard solution
Accurately weighed and transfer 10 mg of Ritonavir and Atazanavir working standard into a 10ml of dry volumetric flasks add about 7ml of Methanol and 3ml of water sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol and water.
Further pipette 0.15ml of the above Ritonavir and 0.45ml of Atazanavir stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.
Procedure:
Inject the samples to the Rp-Hplc by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution and retention for performing validation parameters as per ICH guidelines
Linearity
Accurately measured volumes of working standard solution of Ritonavir and Atazanavir was transferred into a series of 10ml volumetricflasks and diluted appropriately with mobilephase. 10µl of each solution was injected under chromatographic conditions described above. Calibration curves were obtained by plotting the response (area of drug peak) versus concentration of drug. Regression were calculated. The method was found linear over a concentration range of 5-25 μg/mL for Ritonavir and 15-75 μg/mL for Atazanavir respectively.
Procedure for analysis of tablets
15 tablets were weighed and powdered. Accurately weighed portion of this powder equivalent to 10 mg of Ritonavir and 10 mg of Atazanavir was transferred to a 100 ml volumetric flaskcontaining 80 ml of mobile phase. The contents of the flask were allowed to stand for15 minutes with sonication toensure that to complete solubility of the drugs and make up the volume with mobile phase. The above solution was filtered through 0.45μmnylon filter. From this solution appropriate dilutions were made with mobile phase to obtain concentration in calibration range for both the drugs and this solution was used for estimation.With the optimized conditions , a steady baseline was recorded, the mixed working standard solution were injected and the chromatogram was record. The retention times of Ritonavir and Atazanavir were found. The proposed method was found to be specific and no interference from common tablet excipients like starch etc. The response factors of the standard solutions and sample solutions were calculated. The assay was calculated from the equation of regression line for each drug. The assay procedure was repeated for 6 times and the percentage of individual drug in the formulation was calculated. The results of analysis shows that the amount of drug was in good
METHOD VALIDATION SYSTEM SUITABILITY
Accurately weigh and transfer 10 mg of Ritonavir and 10mg of Atazanavir working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)
Further pipette 0.15 ml of Ritonavir and 0.45ml of Atazanavir from the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.
Procedure:
The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits.
SPECIFICITY STUDY OF DRUG: Preparation of Standard Solution:
Accurately weigh and transfer 10 mg of Ritonavir and 10mg of Atazanavir working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.15 ml of Ritonavir and 0.45ml of Atazanavir from the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.
Preparation of Sample Solution:
Take average weight of the Tablet and crush in a mortar by using pestle and weight 10 mg equivalent weight of Ritonavir and Atazanavir sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.
Further pipette 0.15 ml of Ritonavir and 0.45ml Atazanavir above stock solution into a 10ml volumetric flask and dilute up to the mark with diluen
Linearity
The method was linear in the range of150-450μg/mL and 37.5-112.5 μg/mL for ATZ and RIT respectively. Linear regression data was given
Precision
The precision of the method was demonstrated by inter day and intraday studies. In the intraday studies, solutions of standard and sample were repeated 3times in a day and percent relative standard deviation (%RSD) was calculated. The intraday %RSD of Ritonavir and Atazanavir were foundto be 0.54 and 0.8 respectively.In the interday variation studies, injections of standard and sample solutions were made on two days and %RSD was calculated. The interday %RSD for Ritonavir and Atazanavir were found to be 0.5 to0.63 respectively. From the data obtained the developed RP-HPLC method was found to be precise.
Accuracy
The accuracy of the method was determined by recovery experiments. A known amount of concentration of working standard was added to the fixed concentration of the pre-analyzed tablet solution. Percent recovery was calculated by comparing the area before and after the addition of working standard. Forboth the drugs, recovery was performed in the same way. The recovery studies were performed in 3 times This standard addition method was performed at 50%, 100%, 150%level and the percentage recovery wascalculated. Percent recovery was within the range of 98.2 to 99.6 for Ritonavir and 98.2 to99.6 for Atazanavir that indicates method was accurate.
Limit of detection and limit ofquantification
The Limit of detection and quantification were calculated using standard deviation of the response and slope of calibration curve. The LOD for Ritonavir and Atazanavir was found to be 0.54µg/ml and 1.4 µg/mlrespectively. The LOQ is the smallest concentration of the analyte, which gives response that can be accurate. The LOQ was 1.6 µg/ml and 4.4µg/ml for Ritonavir and Atazanavir respectively.
Robustness
Robustness of the method was checked by making slight changes in chromatographic conditions like mobile phase ratio, pH of buffer, flow rate. It was observed that there were no marked changes in chromatograms, which demonstrated that the developed RP-HPLC method is robust.
RESULTS AND DISCUSSION
The proposed method was found to be linear in the concentration range of 5-25µg/mland 15-75 µg/ml for Ritonavir and Atazanavir. The method was specific since excipients in the formulation did not interferein the estimation of Ritonavir and Atazanavir. Accuracy of the method was indicated by recovery values from 98.2 to 99.6 for Ritonavir and 98.2 to99.6 for Atazanavir. Precision is reflectedby %RSD values less than 2. The LOD for Ritonavir and Atazanavir was found to be 0.54µg/ml and 1.4 µg/mlrespectively LOQ was 1.6 µg/ml and 4.4µg/ml for Ritonavir and Atazanavir respectively .Validation parameters were summarized System suitability: The % purity of Ritonavir and Atazanavir in pharmaceutical dosage form was found to be 98.9%.
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